1. Home
  2. FNWB vs IMUX Comparison

FNWB vs IMUX Comparison

Compare FNWB & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Northwest Bancorp

FNWB

First Northwest Bancorp

HOLD

Current Price

$9.85

Market Cap

87.9M

Sector

Finance

ML Signal

HOLD

Logo Immunic Inc.

IMUX

Immunic Inc.

HOLD

Current Price

$0.58

Market Cap

85.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FNWB
IMUX
Founded
1923
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
87.9M
85.8M
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
FNWB
IMUX
Price
$9.85
$0.58
Analyst Decision
Buy
Strong Buy
Analyst Count
1
5
Target Price
$13.50
$6.00
AVG Volume (30 Days)
33.8K
1.3M
Earning Date
01-28-2026
11-13-2025
Dividend Yield
1.42%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$54,052,000.00
N/A
Revenue This Year
$31.86
N/A
Revenue Next Year
$10.64
N/A
P/E Ratio
N/A
N/A
Revenue Growth
6.47
N/A
52 Week Low
$6.05
$0.56
52 Week High
$12.10
$1.39

Technical Indicators

Market Signals
Indicator
FNWB
IMUX
Relative Strength Index (RSI) 58.89 33.77
Support Level $9.88 $0.58
Resistance Level $10.08 $0.70
Average True Range (ATR) 0.17 0.04
MACD -0.06 -0.01
Stochastic Oscillator 12.20 17.72

Price Performance

Historical Comparison
FNWB
IMUX

About FNWB First Northwest Bancorp

First Northwest Bancorp is a bank holding company and a financial holding company and is engaged in banking activities through its wholly owned subsidiary, First Fed Bank, as well as certain non-banking financial activities. It includes deposit and lending transactions that are supplemented with other borrowing and investing activities. The bank's principal lending activities are focused on first lien one- to four-family mortgage loans, commercial and multi-family real estate loans, construction and land loans, commercial business loans, and consumer loans.

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

Share on Social Networks: